Physician profile
James Tetleton
NPI 1891035044
$452.61
in general payments reported to CMS, 2019-2025
10 companies · $33.26 in 2025
The $33.26 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $47.67 · 2022: $209 · 2023: $114 · 2024: $49.13 · 2025: $33.26.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $196.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $78.69 | 2022-2025 | Wegovy |
| Abbvie INC. | $77.91 | 2022-2023 | |
| Otsuka America Pharmaceutical, INC. | $65.44 | 2021-2023 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $62.93 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $48.92 | 2022 | |
| Merck Sharp & Dohme LLC | $38.86 | 2023-2024 | Vaxneuvance, Gardasil 9, Vaxelis |
| Exact Sciences Corporation | $28.92 | 2024 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $18.03 | 2022 | |
| Glaxosmithkline, LLC. | $16.91 | 2021 | |
| Pfizer INC. | $16.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Tetleton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.